1New pharmacological tools:the use of diterpenes to promote adult hippocampal neurogenesisRicardo Gómez-Oliva，Pedro Nunez-Abades，Carmen CastroPerspectives1629-1630
2Clustering of voltage-gated ion channels as an evolutionary trigger of myelin formationHenrike Ohm，Simone Rey，Christian KlämbtPerspectives1631-1632
3Using microglia-derived extracellular vesicles to capture diversity of microglial activation phenotypes following neurological injuryAustyn D.Roseborough，Nikita Ollen-Bittle，Shawn N.WhiteheadPerspectives1633-1634
4Sexual dimorphism of G protein-coupled receptor signaling in the brainSara Aljoudi，Hamdan Hamdan，Khaled S.Abd-ElrahmanPerspectives1635-1636
5Glycolysis and glucose metabolism as a target for bioenergetic and neuronal protection in glaucomaPete A.Williams，Robert J.CassonPerspectives1637-1638
6MAP4K inhibition as a potential therapy for amyotrophic lateral sclerosisShuaipeng Ma，Chun-Li ZhangPerspectives1639-1640
7Role of fullerenols derivative 3HFWC in the treatment of Alzheimer's diseaseSanja Ivkovic，Djuro KorugaPerspectives1641-1642
8Monomeric C-reactive protein:a link between chronic inflammation and neurodegeneration?Nicoleta Arnaut，Ylenia Pastorello，Mark SlevinPerspectives1643-1644
9Alterations of protein homeostasis in Alzheimer's disease:beyond Procrustean bed of endoplasmic reticulum stress and unfolded protein responseDmitry Lim，Alexei VerkhratskyPerspectives1645-1646
10The big data challenge-and how polypharmacology supports the translation from pre-clinical research into clinical use against neurodegenerative diseases and beyondSven Marcel Stefan，Muhammad RafehiPerspectives1647-1648
11p38-MAPK and CDK5,signaling pathways in neuroinflammation:a potential therapeutic intervention in Alzheimer's disease?Vlad Ionut Viorel，Ylenia Pastorello，Nosherwan Bajwa，Mark SlevinPerspectives1649-1650
12Modifying the progression of Parkinson's disease through movement interventions:multimodal quantification of underlying mechanismsManuel Bange，Damian Marc Herz，Dumitru Ciolac，Gabriel Gonzalez-Escamilla，Sergiu GroppaPerspectives1651-1652
13Targeting muscle to treat Charcot-Marie-Tooth diseaseDavid Villarroel-Campos，James N.SleighPerspectives1653-1654
14Suppression of mature TAU isoforms prevents Alzheimer's disease-like amyloid-beta oligomer-induced spine loss in rodent neuronsSarah Buchholz，Hans ZempelPerspectives1655-1657
15Small molecular decoys in Alzheimer's diseaseSho Oasa，Valentina L.Kouznetsova，Igor F.Tsigelny，Lars TereniusPerspectives1658-1659
16Crosstalk among mitophagy,pyroptosis,ferroptosis,and necroptosis in central nervous system injuriesLi Zhang，Zhigang Hu，Zhenxing Li，Yixing LinReviews1660-1670
17Glucagon-like peptide 1 receptor activation:anti-inflammatory effects in the brainYolanda Diz-Chaves，Zainab Maastor，Carlos Spuch，José Antonio Lamas，Lucas C.González-Matías，Federico MalloReviews1671-1677
18Resident immune responses to spinal cord injury:role of astrocytes and microgliaSydney Brockie，Cindy Zhou，Michael G.FehlingsReviews1678-1685
19Use of donepezil for neurocognitive recovery after brain injury in adult and pediatric populations:a scoping reviewAvery L.Miller，Nathan K.Evanson，J.Michael TaylorReviews1686-1695
20The role of snapin in regulation of brain homeostasisJiawen Li，Xinqi Huang，Yumei An，Xueshi Chen，Yiyang Chen，Mingyuan Xu，Haiyan Shan，Mingyang ZhangReviews1696-1701
